22 completed, 2 terminated, 1 withdrawn. 10 Phase 3, 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 9, Terminated 1 |
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
Follow cilgavimab and tixagevimab drug combination: new trials by email Literature Review of cilgavimab and tixagevimab drug combination trials Research Report on cilgavimab and tixagevimab drug combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan Evusheld - COVID-19 | Completed | AstraZeneca | 397 | 2023-12-06 | 2024-06-26 | |
| Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL EVUSHELD - Chronic Lymphocytic Leukemia, COVID-19 | Phase 2 | Withdrawn | Sunnybrook Health Sciences Centre | 2023-10-01 | 2024-04-04 | |
| eVusheld Assessment reaL wORld Effectiveness in DoD Health System EVUSHELD - COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease | Completed | AstraZeneca | 4724 | 2023-08-10 | 2024-09-19 | |
| eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services EVUSHELD - SARS-CoV-2, COVID-19 | Completed | AstraZeneca | 4000 | 2023-03-09 | 2025-01-21 | |
| eVusheld Assessment reaL wORld Effectiveness at UPMC EVUSHELD - SARS-CoV-2, COVID-19 | Completed | AstraZeneca | 4232 | 2023-01-09 | 2024-11-12 | |
| eVusheld Assessment reaL wORld Effectiveness in the VA Health System Evusheld - SARS-CoV-2, COVID-19 | Completed | AstraZeneca | 5814 | 2023-01-04 | 2024-09-03 | |
| Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study) AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort) - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | AstraZeneca | 3882 | 2022-12-16 | 2026-06-18 |
| PREP (Pre-Exposure Prophylaxis) of COVID-19 Evusheld - Immuno-Deficiency, COVID-19 | Completed | Ghady Haidar | 138 | 2022-07-26 | 2024-07-15 | |
| REAl LIfe" Observational Study on the Effectiveness of Evusheld Prophylaxis Against SARS-CoV-2 Omicron Variants in Vaccine Non-responder Immunocompromised Patients Evusheld, Control - SARS-CoV-2 Omicron Variants | Completed | Fondazione IRCCS Policlinico San Matteo di Pavia | 88 | 2022-07-08 | 2026-03-16 | |
| A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19 AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) - Coronavirus Disease 2019 (COVID-19) | Phase 2 | Terminated | AstraZeneca | 251 | 2022-06-09 | 2024-10-23 |
| Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2 Evusheld (tixagevimab+cilgavimab) IM or IV - SARS-CoV-2 Infection | Phase 3 | Terminated | MediMergent, LLC | 550 | 2022-06-03 | 2023-09-08 |
| AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics AZD7442 - SARS-CoV-2 | Phase 1 | Completed | AstraZeneca | 46 | 2022-03-21 | 2025-04-18 |
| Non-inferiority Trial on Treatments in Early COVID-19 Sotrovimab, Tixagevimab Cilgavimab, Nirmatrelvir Ritonavir - COVID-19 | Phase 3 | Completed | Azienda Ospedaliera Universitaria Integrata Verona | 536 | 2022-03-07 | 2023-11-07 |
| A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults 600 mg AZD7442 IV, 600mg placebo IV - Coronavirus Disease 2019 (COVID-19) | Phase 2 | Completed | AstraZeneca | 272 | 2021-12-03 | 2024-11-21 |
| Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants AZD7442, AZD8895 (clonal cell line material), AZD1061 (clonal cell line material) - Corona Virus Disease | Phase 1 | Completed | AstraZeneca | 224 | 2021-11-30 | 2024-11-25 |
| A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults AZD7442 IM, Placebo IM, AZD7442 IV - Coronavirus Disease 2019 (COVID-19), Healthy Volunteer | Phase 1 | Completed | AstraZeneca | 61 | 2021-10-09 | 2023-03-31 |
| Phase I Double-blind, Placebo-controlled Study of AZD7442 AZD7442 300 mg IM(male), AZD7442 600 mg IM (male), AZD7442 300 mg IV (male and female) - COVID-19 | Phase 1 | Completed | AstraZeneca | 40 | 2021-03-16 | 2022-06-27 |
| AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) AZD7442, Placebo, Remdesivir - COVID-19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 1455 | 2021-02-10 | 2025-02-04 |
| Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults AZD7442, Placebo - COVID-19 | Phase 3 | Completed | AstraZeneca | 910 | 2021-01-28 | 2023-07-05 |
| Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults AZD7442, Placebo - COVID-19 | Phase 3 | Completed | AstraZeneca | 1131 | 2020-12-02 | 2023-11-21 |
Showing 20 of 25. Sign in to see all of them.
COVID-19 (23) · Coronavirus Infections (8) · Coronaviridae Infections (3) · Nidovirales Infections (3) · RNA Virus Infections (3) · Severe Acute Respiratory Syndrome (3) · Virus Diseases (3) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Pneumonia (1)
AstraZeneca (16) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Azienda Ospedaliera Universitaria Integrata Verona (1) · Fondazione IRCCS Policlinico San Matteo di Pavia (1) · Ghady Haidar (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · MediMergent, LLC (1) · Sunnybrook Health Sciences Centre (1)
United States (15) · United Kingdom (8) · Spain (5) · Belgium (4) · Poland (4) · Brazil (3) · Canada (3) · Denmark (3) · France (3) · Germany (3) · Greece (3) · Italy (3) · Japan (3) · Singapore (3) · Argentina (2)
Myron Levin, MD (2) · David Smith, MD, MAS (1) · Donald M Yealy, MD (1) · Florence Ader, MD (1) · Ghady Haidar, MD (1) · James Neaton, Prof. (1) · Jens Lundgren, Prof. (1) · Pablo Forte Soto, MD, MSc, PhD (1) · Prof. James Neaton (1) · Prof. Jens Lundgren (1) · Ralph Boccia, MD (1) · Scott L DuVall, PhD (1)
PMID 34473343, PMID 35713300, PMID 35817072, PMID 38703336, PMID 32304640, PMID 33264556, PMID 33356051, PMID 34048876, PMID 34350582, PMID 34534511, PMID 34928698, PMID 34953520, PMID 34981077, PMID 35233617, PMID 35298440, PMID 35443106, PMID 35512728, PMID 35533972, PMID 35643099, PMID 35688164, PMID 35793677, PMID 35797235, PMID 35939810, PMID 35995785, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36411267, PMID 36467293, PMID 36661240, PMID 36683419, PMID 36695483, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37279602, PMID 37280116, PMID 37524201, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37728045, PMID 37751015, PMID 37855026, PMID 37948759, PMID 38367705, PMID 38403865, PMID 38552208